Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.
Several other brokerages also recently issued reports on AYTU. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Ascendiant Capital Markets boosted their price objective on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Aytu BioPharma presently has an average rating of “Hold” and an average price target of $10.75.
View Our Latest Stock Analysis on AYTU
Aytu BioPharma Stock Performance
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The firm had revenue of $12.41 million for the quarter, compared to analyst estimates of $12.05 million. As a group, analysts expect that Aytu BioPharma will post -0.73 earnings per share for the current year.
Hedge Funds Weigh In On Aytu BioPharma
Several large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in Aytu BioPharma by 23.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after purchasing an additional 8,222 shares during the period. Persistent Asset Partners Ltd grew its position in Aytu BioPharma by 27.2% in the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares during the last quarter. Rothschild Wealth LLC bought a new position in shares of Aytu BioPharma during the 4th quarter worth about $52,000. BlackRock Inc. bought a new position in shares of Aytu BioPharma during the 2nd quarter worth about $49,000. Finally, XTX Topco Ltd acquired a new position in shares of Aytu BioPharma during the fourth quarter valued at about $67,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.
Aytu BioPharma Company Profile
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.
Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.
Read More
- Five stocks we like better than Aytu BioPharma
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
